Antisense Therapeutics (ASX: ANP)

Currency in -

Last close As at 07/06/2023


−0.01 (−5.32%)

Market capitalisation


Antisense Therapeutics is an Australia-based biopharmaceutical company developing and commercialising Antisense pharmaceuticals for rare diseases. The company’s lead clinical asset is ATL1102, an ASO therapy being investigated for the treatment of DMD.

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (8.6) (1.1) (33.3)
Relative (5.6) (0.5) (29.0)
52 week high/low A$0.1/A$0.1


Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.

Further insights


Healthcare Week 2023

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free